News & Updates

Show Multimedia Only

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

13 Apr 2026 by

Biomarker testing where appropriate and novel tailored combination therapies targeting multiple pathways simultaneously may address the high unmet need and optimize treatment outcomes in hormone receptor–positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (mBC) patients who develop resistance or have disease recurrence while on endocrine-based therapy (ET), said Professor Sherko Kümmel of the Interdisciplinary Breast Unit Clinics, Essen-Mitte, Germany, who spoke at the 14^th Asia-Pacific Breast Cancer Summit (APBCS 2026).

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

13 Apr 2026

LEVI-04 improves knee osteoarthritis outcomes

13 Apr 2026

Treatment with LEVI-04—a p75 neurotrophin receptor (p75NTR) fusion protein that inhibits neurotrophin-3—helps improve pain and function in patients with knee osteoarthritis, as shown in a phase II trial.

LEVI-04 improves knee osteoarthritis outcomes

13 Apr 2026

Semaglutide & liraglutide lower risk of worsening mental illness

13 Apr 2026 by

Use of semaglutide and, to a lesser extent, liraglutide is associated with significantly lower risk of worsening mental illness in patients with depression or anxiety vs non-use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a national cohort study has found.

Semaglutide & liraglutide lower risk of worsening mental illness

13 Apr 2026

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026 by

Perioperative treatment with enfortumab vedotin and pembrolizumab (EV plus pembro) significantly improves event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rates in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, according to the KEYNOTE-905 trial presented at EAU26.

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026

Inhaled mebufotenin shows promise in treatment-resistant depression

12 Apr 2026

Single-day treatment with GH001, a synthetic formulation of inhaled mebufotenin, has been shown to be well tolerated and yield substantial improvements in depressive symptoms in patients with treatment-resistant depression in a phase IIb trial.

Inhaled mebufotenin shows promise in treatment-resistant depression

12 Apr 2026

Baduanjin lowers SBP in individuals with high-normal BP

12 Apr 2026

A traditional Chinese qigong exercise, Baduanjin, has been shown in a recent study to reduce systolic blood pressure (SBP) after 3 months of intervention in people with high-normal BP.

Baduanjin lowers SBP in individuals with high-normal BP

12 Apr 2026

Vaginal platelet-rich plasma injection boosts sexual function in premenopausal women

12 Apr 2026

Administering platelet-rich plasma injections to the anterior vaginal wall helps improve sexual function in sexually active premenopausal women without severe sexual dysfunction, according to a pilot, single-centre study.

Vaginal platelet-rich plasma injection boosts sexual function in premenopausal women

12 Apr 2026

Transurethral ultrasound ablation outperforms prostatectomy in early trial results

11 Apr 2026 by

The minimally invasive MRI-guided transurethral ultrasound ablation (TULSA) for prostate cancer is associated with better safety and periprocedural outcomes compared with robotic prostatectomy, according to the early results of the phase III CAPTAIN trial.

Transurethral ultrasound ablation outperforms prostatectomy in early trial results

11 Apr 2026

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

11 Apr 2026 by

Genetic markers, both in and outside the immune system, influence an individual’s response to the SARS-CoV-2 vaccine, and these effects are similar in patients with or without systemic autoimmune diseases (SADs), reports a study.

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

11 Apr 2026

Semaglutide confers ASCVD risk factor benefits in high-risk patients

11 Apr 2026

Treatment with semaglutide yields early and sustained improvements in multiple atherosclerotic cardiovascular disease (ASCVD) factors in high-risk patients with type 2 diabetes (T2D) and ASCVD and/or chronic kidney disease (CKD), according to a post hoc analysis of the SOUL trial.

Semaglutide confers ASCVD risk factor benefits in high-risk patients

11 Apr 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

LEVI-04 improves knee osteoarthritis outcomes

LEVI-04 improves knee osteoarthritis outcomes

Semaglutide & liraglutide lower risk of worsening mental illness

Semaglutide & liraglutide lower risk of worsening mental illness

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

Inhaled mebufotenin shows promise in treatment-resistant depression

Inhaled mebufotenin shows promise in treatment-resistant depression

Baduanjin lowers SBP in individuals with high-normal BP

Baduanjin lowers SBP in individuals with high-normal BP

Vaginal platelet-rich plasma injection boosts sexual function in premenopausal women

Vaginal platelet-rich plasma injection boosts sexual function in premenopausal women

Transurethral ultrasound ablation outperforms prostatectomy in early trial results

Transurethral ultrasound ablation outperforms prostatectomy in early trial results

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

Semaglutide confers ASCVD risk factor benefits in high-risk patients

Semaglutide confers ASCVD risk factor benefits in high-risk patients